Meeting
2022 ASCO Annual Meeting
Methylated DNA markers in urine aid in the selective identification of patients with prostate cancer as well as clinically significant pathology.
Authors
Paras Shah
Mayo Clinic, Rochester, MN
Paras Shah , William R. Taylor , Brianna J. Gysbers , Douglas W. Mahoney , Sara S. Then , Mary E. Devens , Patrick H. Foote , Karen A. Doering , Kelli Burger , Brandon Nikolai , Michael W. Kaiser , Hatim T. Allawi , John B. Kisiel , Matthew Gettman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5091)
DOI
10.1200/JCO.2022.40.16_suppl.5091
Abstract #
5091
Poster Bd #
274
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Exploring the utility of prostate-derived extracellular vesicles as a urine biomarker for clinically significant prostate cancer.
First Author: Ekamjit Singh Deol
Poster
2016 Genitourinary Cancers Symposium
The risk-based STHLM3 model to improve prostate cancer testing in men 50-69 years: Further health, economic, and clinic evaluation.
First Author: Henrik Gronberg
Poster
2012 ASCO Annual Meeting
Detecting prostate cancer in BRCA1 and BRCA2 mutation carriers: A role for EN2?
First Author: Emma Killick
Poster
2022 ASCO Annual Meeting
Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.
First Author: Eugene Shenderov